StemLife - Brunei

About

Established in 2001, StemLife Berhad (“StemLife” or the “Company”) is Malaysia’s pioneer private stem cell bank. The Company is a subsidiary of Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), a Singapore Exchange-listed company that operates the largest network of stem cell banks in Asia and has earned the trust of over 600,000 parents. StemLife and the Group have facilitated 77 cord blood releases to 21 healthcare institutions across 10 countries, supporting stem cell transplants and cellular therapies.

StemLife is committed to ensuring that their clients can use their cord blood anywhere in the world by obtaining a licence from the Malaysian Ministry of Health and accreditation from the AABB, a global leader in establishing patient safety standards for blood banking, transfusion medicine, blood management, and cellular therapies. Beyond cord blood banking, StemLife offers cryopreservation services for cord lining, cord tissue, and umbilical cord mesenchymal stem cells, along with stem cell expansion through collaboration with a cGMP laboratory.

StemLife also provides various diagnostic services, including non-invasive prenatal testing (NIPT), chromosomal microarray analysis, newborn metabolic screening and talent genetic screening. For more information, please visit https://stemlife.com/.

The Cordlife Group is composed of:

• ​Cordlife Group Limited – Singapore
• Cordlife (Hong Kong) Limited - Hong Kong & Macau
• Health Baby Biotech (Hong Kong) Co., Limited – Hong Kong & Macau
• Cordlife Sciences India Pvt Limited - India & Bangladesh
• PT Cordlife Persada - Indonesia
• Cordlife Medical Philippines, Inc. – the Philippines
• StemLife Berhad – Malaysia & Brunei
• THAI StemLife - Thailand, Myanmar, Laos, Cambodia
• CL Biotech Company Limited – Vietnam

Business Experience

StemLife has been a trusted leader in Malaysia’s stem cell banking industry since 2001. With a strong commitment to quality, the company follows strict procedures to ensure the safe collection, precise processing, and secure storage of cord blood, earning the trust of families seeking reliable healthcare solutions.

In 2004, StemLife made history as the first company in Malaysia to release a cord blood unit for a sibling transplant to treat Acute Myelogenous Leukemia (AML). Since then, the company has released more cord blood units to support treatments for conditions such as cerebral palsy, thalassemia major, leukemia, and brain injuries. By ensuring the quality and readiness of stored stem cells, StemLife has helped families in critical moments. As part of a global network, the company has facilitated the release of 77 cord blood units to 21 healthcare institutions across 10 countries, demonstrating its significant international reach.

In 2014, StemLife became the first and only stem cell bank in Malaysia to offer families the option to store three types of stem cells from the umbilical cord: Haematopoietic Stem Cells (HSC) from cord blood, Mesenchymal Stem Cells (MSC) from cord tissue, and Epithelial Stem Cells (EpSC) from the cord lining. This breakthrough provides families with more possibilities for future medical treatments.

StemLife’s services are strengthened through its partnership with a cGMP-certified laboratory approved by the National Pharmaceutical Regulatory Agency (NPRA) and the Ministry of Health (MOH). This collaboration ensures access to advanced expertise and cutting-edge infrastructure for processing, harvesting, and expanding Mesenchymal Stem Cells (MSC), all while maintaining the highest industry and regulatory standards.

The company consistently meets global quality benchmarks. In 2024, StemLife received its fourth consecutive accreditation from AABB, the international gold standard for cord blood banking. It also became the first cord blood bank in Malaysia to achieve both the Good Distribution Practice for Medical Devices (GDPMD) Certification and the Establishment Licence. StemLife is fully licensed by the Ministry of Health and holds the MS ISO 15189:2022 accreditation, further demonstrating its commitment to quality and compliance.

Beyond cord blood banking, StemLife is expanding into diagnostic services to offer families a wider range of healthcare solutions. This growth reflects the company’s ongoing focus on innovation and its mission to provide greater value to clients.

With a proven track record of quality, care, and innovation, StemLife remains at the forefront of stem cell banking and healthcare services, helping families secure their future health and well-being.

Collection Kit

The collection kit includes a sterile, double-wrapped blood bag pre-filled with the anticoagulant CPDA-1 and blood collection set for maternal blood.

Transportation Container

StemLife utilizes the StemCool shipping system, featuring thermal insulation and an IATA-compliant protective shield, to maintain ambient temperature during transport back to the laboratory.

Shipping Info

The umbilical cord blood sample will be hand-delivered using our StemCool shipping system. This provides a secure time and temperature protocol that has been proven effective in maintaining stem cells within the range of optimal temperature.

Processing Method

Stem cells are processed using the AXP® II System, a globally recognised automated technology from the USA. This system ensures safe and efficient harvesting of stem cells, meeting international standards for transplants and treatments.

Components Stored

The final component stored is 20ml of the "buffy coat" layer of the blood, which holds both white cells and stem cells. Parents are provided with lab report describing:

• Cord blood: volume, Total Nucleated Cell (TNC) count, CD34+ stem cell count, CD34+ stem cell viability, ABO typing and sterility.
• Maternal blood: Infectious disease status for HIV, Hepatitis B, Hepatitis C, Syphilis, CMV IgM, CMV IgG and HTLV

Storage Method

Cord blood stem cells are stored in a 25 mL cryobag encased in a metal cassette. These metal cassettes provide an additional barrier of protection. Stem cell units are stored in the vapour phase of cryogenic liquid nitrogen tanks at temperatures approximately -196⁰C.

Licensing & Accreditation

• Cord Blood & peripheral blood stem cells (PBSC) licensed by Ministry of Health Malaysia under the PHFS Act 1998.
• Accredited by the international cord blood banking gold standard AABB.
• MS ISO 151897 accredited – Medical Lab Testing.
• Good Distribution Practice for Medical Device (GDPMD) Certification and the Establishment License
• Participation in College of American Pathologists USA program since 2003.
• Participation in Royal College of Pathology Australia program since 2012.
• Cleanroom class 1,000 and 10,000 certified.

Clinical Experience

To date, StemLife and its Group has successfully released 77 cord blood units and 21 cord lining units to support stem cell transplantation and infusions. StemLife has established its track record with the largest number of stem cell transplants done in Malaysia through its 23 years of experience in stem cell banking, working closely with third party medical expertise. StemLife has released over 500 peripheral blood stem cell units for therapies.

Guarantees

StemLife clients will be covered by additional protection benefits as follows:

1) Stem Assist - StemLife offers coverage of possible pregnancy complications and congenital illnesses of baby to give you greater peace of mind. (*This is exclusively for our Cordmax+ clients.)

2) StemLife Assured - StemLife assures you of a suitable cord blood unit or RM100,000* to defray medical costs if your cord blood unit loses its viability at the point of transplant.

3) Stem Shield Plus - A one-time lump sum subsidy of MYR110,000** will be provided to partially defray medical costs of transplantation for the child whose umbilical cord blood unit is stored.

4) Stem Courier - Your baby’s precious cord blood will be taken care by our dedicated staff during the transportation from the hospital to our laboratory. In the event of a total loss of cord blood during transit, StemLife will offer a lump sum payout of RM25,000*.

5) Stem 21 - StemLife, together with an International insurer, offers a lump sum payout of MYR 5,000** to cover the remaining cost of cord blood storage if you or your spouse passes on or suffers from Total and Permanent Disability (TPD).

6) Stem Affirm - StemLife will cover the cost of human leukocyte antigen (HLA) and colony forming unit (CFU) testing* prior to a haematopoietic stem cell transplant ordered by your physician. These tests are mandated by Malaysian Ministry of Health and international quality standards.

7) StemLife Cord Blood Network - Protecting 3 Generations of your Family. Tapping into one of Asia’s largest cord blood networks, StemLife will assist in the search for a matching cord blood unit, should there be a need of a cord blood transplant for your child, his/her biological parents and biological grandparents.

* terms & conditions apply.

Prices

Our sales consultants will tailor a package plan to suit your needs. We offer instalment plans of up to 24 months with zero interest for your convenience,

For more information, book an appointment with our consultant, call our 24-hour careline at +603 2779 0033, or email us at info@stemlife.com.

Additional Services

1. Banking services:
   1. Umbilical Cord Lining (UCL) banking –Exclusively available with StemLife’s patented CellOptima™ technology, UCL contains highly potent Mesenchymal Stem Cells (MSC) from cord tissue and Epithelial Stem Cells (CL-EpSCs). These stem cells are undergoing clinical trials for their potential to treat conditions such as stroke, cardiovascular diseases, autism, Alzheimer’s disease, soft tissue repair, eye disorders, and other conditions.
   2. Umbilical Cord Tissue (UCT) banking –a rich source of Wharton’s jelly from the umbilical cord tissue, which contains versatile Mesenchymal stem cells (MSCs) with advanced expansion capabilities for future medical use.
   3. Mesenchymal Stem Cells (MSC) Expansion- involves expanding MSCs under controlled conditions to ensure they remain viable and expandable, providing a reliable solution for future medical applications.
   4. Peripheral Blood Banking & Services- Harvesting and storing Hematopoietic Stem Cells (HSCs) from mobilised peripheral blood, which are commonly used to treat blood disorders and cancers.

2. Diagnostic services
   1. Non-invasive prenatal testing (NIPT) – A maternal blood test that screens for the most common chromosomal abnormalities such as Down syndrome as early as 10 weeks of pregnancy. For more information, please visit https://biotech.stemlife.com/nipt/
   2. Chromosomal Microarray Analysis- a first-tier diagnostic tool for detecting foetal structural issues, offering more accurate results than standard karyotyping
   3. Talent Genetic Screening- evaluates genetic markers associated with learning, cognitive abilities and potential aptitudes in areas such as sports and creativity. It provides valuable insights into a child’s inherent strengths and developmental opportunities.
   4. Newborn metabolic screening - The most comprehensive non-invasive newborn metabolic screening that can detect more than 100+ congenital metabolic disorders (or known as inborn error metabolism) from specimens of the newborn’s urine . For more information, please visit https://biotech.stemlife.com/about-metascreen/
   5. Baby Genetic Screening- A newborn genetic screening test that screens 0-3 years old babies with more than 120 conditions caused by chromosomal abnormalities and disease-causing gene variants, providing an expanded insight into the baby’s health condition. For more information, please visit https://biotech.stemlife.com/about-bebegene/ .